reported second-quarter earnings that met analysts' estimates, as the period was spurred by strong sales growth in coronary stents and implantable defibrillators and across the board growth in all product lines.
For the second quarter ended Oct. 27, Medtronic earned $314 million, or 26 cents a share, which was in line with estimates, according to
First Call/Thomson Financial
. The company earned $261 million, or 21 cents a share, a year ago.
The Minneapolis-based medical devices and technology company reported second-quarter sales of $1.36 billion, compared with $1.19 billion last year.